Stock DNA DNA GROUP (T.R.) LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dna Group (T.R.) Ltd

Equities

DNA

IL0011038523

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 15:25:00 15/05/2024 BST 		5-day change 1st Jan Change
93.7 ILa 0.00% Intraday chart for Dna Group (T.R.) Ltd +0.97% +48.26%
03-19 Dna Group (T.R.) Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Dna Group (T.R.) Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 32.47 20.61 22.9 157.2 87.04 77.84
Enterprise Value (EV) 1 31.98 20.23 23.14 133.5 21.32 11.14
P/E ratio -2.15 x -0.44 x -1.17 x 7.58 x -3.6 x -63.2 x
Yield - - - - - -
Capitalization / Revenue - - - - 155,436,730 x 254,378,141 x
EV / Revenue - - - - 38,063,516 x 36,410,820 x
EV / EBITDA - - - - - -
EV / FCF 5.63 x -1.96 x 5.87 x -12.5 x 55.2 x -7.75 x
FCF Yield 17.8% -50.9% 17% -8.01% 1.81% -12.9%
Price to Book 0.5 x 0.73 x 2.88 x 2.89 x 1.12 x 0.98 x
Nbr of stocks (in thousands) 24,601 30,260 30,826 99,678 119,567 123,164
Reference price 2 1.320 0.6810 0.7430 1.577 0.7280 0.6320
Announcement Date 28/03/19 12/04/20 31/03/21 31/03/22 29/03/23 19/03/24
1ILS in Million2ILS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - 0.56 0.306
EBITDA - - - - - -
EBIT 1 -2.116 -2.412 -1.592 -2.367 -5.699 -2.174
Operating Margin - - - - -1,017.68% -710.46%
Earnings before Tax (EBT) 1 -14.29 -38.53 -19.26 18.37 -23.54 -1.177
Net income 1 -14.29 -38.53 -19.26 18.37 -23.54 -1.177
Net margin - - - - -4,202.86% -384.64%
EPS 2 -0.6133 -1.542 -0.6330 0.2080 -0.2020 -0.0100
Free Cash Flow 1 5.684 -10.31 3.943 -10.69 0.3861 -1.438
FCF margin - - - - 68.95% -469.85%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 28/03/19 12/04/20 31/03/21 31/03/22 29/03/23 19/03/24
1ILS in Million2ILS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0.24 - - -
Net Cash position 1 0.49 0.37 - 23.7 65.7 66.7
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 5.68 -10.3 3.94 -10.7 0.39 -1.44
ROE (net income / shareholders' equity) -21.3% -82.8% -107% 59% -35% -1.48%
ROA (Net income/ Total Assets) -1.67% -2.57% -3.6% -4.05% -5.21% -1.67%
Assets 1 857.8 1,501 534.7 -454 451.3 70.45
Book Value Per Share 2 2.640 0.9300 0.2600 0.5400 0.6500 0.6400
Cash Flow per Share 2 0.0200 0.0100 0 0.2400 0.5300 0.5400
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 28/03/19 12/04/20 31/03/21 31/03/22 29/03/23 19/03/24
1ILS in Million2ILS
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DNA GROUP (T.R.) LTD Stock Dna Group (T.R.) Ltd
+48.26% 31.22M
MODERNA, INC. Stock Moderna, Inc.
+29.41% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.63% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.78% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.19% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.95% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.37% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DNA Stock
  4. Financials Dna Group (T.R.) Ltd